Tag: af (atrial fibrillation)

Lower Post-TAVR Mortality Seen on DOAC vs VKA When OAC Indicated

Following a transcatheter aortic valve replacement (TAVR), direct oral anticoagulants (DOACs) are preferable to vitamin K antagonists (VKAs) in patients who are candidates for oral...

Political Support of Permanent DST Concerns Sleep Scientists

The reintroduction of congressional bills that aim to end seasonal time change and move permanently to daylight saving time (DST) – and action on the...

Extended AF Monitoring Worth Considering After Eye Stroke

Extended cardiac monitoring for the detection of atrial fibrillation (AF) should be considered in patients who have a stroke caused by central retinal artery occlusion,...

Finerenone Cuts New AF in Type 2 Diabetes and CKD

Finerenone treatment of patients with type 2 diabetes and diabetic kidney disease was linked to a significant drop in the incidence of new-onset atrial fibrillation as...

New AHA Guidance on Obesity and Cardiovascular Risk

An updated American Heart Association scientific statement on the role of obesity in cardiovascular disease provides the first new guidance in 15 years, drawing on...

Paroxysmal AF Can Recur but Burden Plunges After Durable Ablation

A randomized comparison of two ablation catheter designs in patients with paroxysmal atrial fibrillation (AF) may say less about the choice of equipment than the...

Parity Whether Anticoagulation Is Halted or Not for Unplanned Cath

Maintaining oral anticoagulation (OAC) throughout an unplanned cardiac catheterization confers no extra risk and might hold some advantages over periprocedural OAC interruption in patients on...

New-onset Arrhythmias Low in COVID-19 and Flu

New onset atrial fibrillation or flutter (AF/AFL) is uncommon in patients hospitalized with COVID-19 and occurs at a rate similar to that seen in patients...

Using AI, Mobile ECG Aims to Expand QTc Screening Horizons

Mobile electrocardiography (mECG) devices can go places a standard 12-lead electrocardiography system can’t, with fewer technicians in tow, but it doesn’t have the same functionality...

Curious Variation in AF Incidence, Mortality Across Europe

The prevalence of atrial fibrillation (AF) and its related mortality have been holding fairly steady in Europe overall during the past 3 decades, but a...

First Experience With Completely Leadless CRT

Totally leadless cardiac resynchronization therapy (CRT) combining the Micra transcatheter pacing system and a WiSE-CRT system was feasible and associated with significant acute QRS reduction...

Digoxin a ‘Viable Alternative’ in AF With HF: RATE-AF Published

A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker...

Biomarker May Flag Response to Novel AF Intervention

Neuropeptide Y (NPY), a sympathetic cotransmitter, might provide a clue to which patients with atrial fibrillation (AF) will respond to vagal nerve stimulation to decrease AF...

New-Onset AF Common But Unrecognized Early After Cardiac Surgery

One in five patients at elevated stroke risk who underwent cardiac surgery with no history of atrial fibrillation preoperatively or at discharge developed postoperative AFib...

Rivaroxaban Rivals Warfarin in AF, Mitral Bioprosthesis

The direct oral anticoagulants (DOACs) took cardiology by storm a decade ago when trials showed they were at least as safe and effective as warfarin...

No Secondary Prevention Benefit With Omega-3s in Elderly

Omega-3 fatty acids on top of standard care did not reduce major cardiovascular events or death in elderly survivors of an acute myocardial infarction (MI)...

STRENGTH Trial Questions CV Benefit of High-Dose Omega-3s

Questions about the cardiovascular benefit of omega-3 fatty acids and the high-dose eicosapentaenoic acid (EPA) product, icosapent ethyl (Vascepa, Amarin), have resurfaced with the presentation...

Omega-3, Vit-D Both Fail at AF Primary Prevention in VITAL-Rhythm

Clinical trials of omega-3 fatty acid or vitamin D supplements have followed a long and winding road in search of benefits in cardiovascular (CV) disease,...

Study Questions Routine Long-term Beta-Blocker Post MI

Current American and European guidelines recommending long-term beta-blocker therapy following an acute MI appear to be obsolete in the modern reperfusion era, suggests an analysis...

‘Cautious’ DOAC Underdosing in AF May Push Mortality Higher

The risk for death goes up for patients with atrial fibrillation (AF) who are put on direct oral anticoagulants (DOAC) at dosages other than those...

‘Low-Risk’ Valvular AF in Some May Warrant Oral Anticoagulation

Some patients with “valvular” atrial fibrillation (AF) and stroke-risk scores low enough for oral anticoagulation (OAC) not to be indicated may actually face enough thromboembolic...

New ESC/EACTS Guideline on Atrial Fibrillation

New atrial fibrillation management guidelines from the European Society of Cardiology (ESC) call for diagnostic confirmation and structured characterization of AF and the need to...

RATE-AF Trial Boosts Digoxin for Rate Control in Permanent AF

Digoxin now deserves to be considered first-line therapy for long-term heart rate control in older patients with permanent atrial fibrillation and symptoms of heart failure,...

Early Rhythm Control in AF Gains New Life

Initiation of rhythm control with antiarrhythmic drugs and/or ablation in patients with early, recently diagnosed atrial fibrillation led to a significantly lower risk for major...

A Tenuous Step Forward for Pulsed Field Ablation in Persistent AF

Pulsed field ablation (PFA) targeting areas beyond the pulmonary vein appeared to provide short-term lesion control without esophageal injury in persistent atrial fibrillation (AF) in...